IV carbamazepine authorized in the US
12th October 2016
The FDA has authorized a parenteral formulation of carbamazepine (Carnexiv; Lundbeck) for short-term replacement therapy for oral forms of the drug in adults with certain seizure types when oral administration is temporarily not feasible.
The IV total daily dose is 70% of the PO total daily dose of carbamazepine, and should be divided equally into four infusions to be administered q6h. Each dose should be diluted in 100mL of diluent and infused IV over 30 minutes.
The company has not yet filed for a marketing authorization in Europe.
- IV carbamazepine authorized in the US
- PCF5+ 2016 pdf available soon!
- Palladone (hydromorphone) SPC updated
- Authorized glycopyrronium oral solution now available in UK
- NICE Consultation: Care of dying adults in the last days of life
- NICE guidance on multimorbidity
- British guideline on management of asthma updated
- SMC accepts diamorphine nasal spray
- Updated Do Not Attempt Cardiopulmonary Resuscitation policy published in Scotland
- Cochrane review: oxycodone for neuropathic pain